Publications by authors named "Cesare Lancellotti"
Tissue Biomarkers are information written in the tissue and used in Pathology to recognize specific subsets of patients with diagnostic, prognostic or predictive purposes, thus representing the key elements of Personalized Medicine. The advent of Artificial Intelligence (AI) promises to further reinforce the role of Pathology in the scenario of Personalized Medicine: AI-based devices are expected to standardize the evaluation of tissue biomarkers and also to discover novel information, which would otherwise be ignored by human review, and use them to make specific predictions. In this review we will present how AI has been used to support Tissue Biomarkers evaluation in the specific field of Pathology, give an insight to the intriguing field of AI-based biomarkers and discuss possible advantages, risk and perspectives for Pathology.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the effects of a sudden shift to digital pathology during the COVID-19 pandemic on diagnostic accuracy and pathologist perceptions.
- It involved 17 participants who analyzed archived test cases and completed a survey, with results compared to traditional microscopy methods.
- The findings showed a 9% overall error rate, suggesting that while transition duration may not impact performance, senior pathologists faced challenges adapting to digital methods, potentially leading to discrepancies in diagnoses.*
Article Synopsis
- In late February, the Lombardy region in Italy became a hotspot for COVID-19, leading to significant challenges for healthcare workers, particularly in Pathology departments.
- Pathology Departments are reorganizing how they handle samples according to National and WHO guidelines, which includes reducing staff and allowing remote work for pathologists due to fewer surgical procedures.
- All human specimens are treated as potentially infectious and require clear clinical information on COVID-19 status, emphasizing the importance of training and common sense for Pathology staff.
Colorectal cancer (CRC) is a neoplastic disease in which normal mucosa undergoes a process of malignant transformation due to the progressive accumulation of molecular alterations affecting proto-oncogenes and oncosuppressor genes. Some of these modifications exert their carcinogenic potential by promoting a constitutive activation of the β-catenin signaling proliferation pathway, and when present, loss of cadherin expression also significantly contributes to the same effect. Using a combined approach of molecular and immunohistochemical analysis, we have previously demonstrated that most sporadic CRCs exhibit a down-regulated expression of a cadherin, named μ-protocadherin, that is generally observed in association with a higher proliferation rate and a worse prognosis.
View Article and Find Full Text PDFWe report a case of a 59-year-old woman with peritoneal malignant mesothelioma and no previous exposure to asbestos with a diagnosis of bilateral ovarian serous borderline tumour with peritoneal implants one year before. We discuss the histopathological and immunohistochemical findings to explain possible and potential interactions between the two diseases. To our knowledge, the association of both serous borderline ovarian tumour and malignant peritoneal mesothelioma has never been described before in the same woman and in such a tight temporal connection.
View Article and Find Full Text PDFAberrant methylation of multiple promoter CpG islands could be related to the biology of ovarian tumors and its determination could help to improve treatment strategies. DNA methylation profiling was performed using the Methylation Ligation-dependent Macroarray (MLM), an array-based analysis. Promoter regions of 41 genes were analyzed in 102 ovarian tumors and 17 normal ovarian samples.
View Article and Find Full Text PDF